Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We are a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for selectively silencing and regulating the expression of specific genes. Since many diseases are caused by the inappropriate activity of specific genes, the ability to silence genes selectively through RNAi could provide a new way to treat a wide range of human diseases. We believe that drugs that work through RNAi have the potential to become a broad new class of drugs, like small molecule, protein and antibody drugs. Using our intellectual property and the expertise we have built in RNAi, we are developing a set of biological and chemical methods and know-how that we apply in a systematic way to develop RNAi therapeutics for a variety of diseases. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-1.48 |
| Quarterly EPS Est: | -0.34 |
| PEG Ratio: | -.02 |
|
Mean Recommendation: View Summary / View All |
1.6 |
Data is provided by Zacks Investment Research
